245 related articles for article (PubMed ID: 32729064)
1. COVID-19: A Concern for Cardiovascular Disease Patients.
Sharma S
Cardiovasc Toxicol; 2020 Oct; 20(5):443-447. PubMed ID: 32729064
[TBL] [Abstract][Full Text] [Related]
2. Association of ACE2 receptor and ACEIs/ARBs with disease severity in COVID-19.
Sinha S; Sehgal A; Sehgal R
Drug Discov Ther; 2020; 14(4):161-170. PubMed ID: 32908071
[TBL] [Abstract][Full Text] [Related]
3. ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV.
Lubbe L; Cozier GE; Oosthuizen D; Acharya KR; Sturrock ED
Clin Sci (Lond); 2020 Nov; 134(21):2851-2871. PubMed ID: 33146371
[TBL] [Abstract][Full Text] [Related]
4. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
Young MJ; Clyne CD; Chapman KE
J Endocrinol; 2020 Nov; 247(2):R45-R62. PubMed ID: 32966970
[TBL] [Abstract][Full Text] [Related]
5. COVID-19, ACE2, and the cardiovascular consequences.
South AM; Diz DI; Chappell MC
Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1084-H1090. PubMed ID: 32228252
[TBL] [Abstract][Full Text] [Related]
6. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
Cheng H; Wang Y; Wang GQ
J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 and Cardiovascular Disease.
Clerkin KJ; Fried JA; Raikhelkar J; Sayer G; Griffin JM; Masoumi A; Jain SS; Burkhoff D; Kumaraiah D; Rabbani L; Schwartz A; Uriel N
Circulation; 2020 May; 141(20):1648-1655. PubMed ID: 32200663
[TBL] [Abstract][Full Text] [Related]
8. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
Lores E; Wysocki J; Batlle D
Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases.
Askin L; Tanrıverdi O; Askin HS
Arq Bras Cardiol; 2020 Jun; 114(5):817-822. PubMed ID: 32491073
[TBL] [Abstract][Full Text] [Related]
10. Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection.
Robinson FA; Mihealsick RP; Wagener BM; Hanna P; Poston MD; Efimov IR; Shivkumar K; Hoover DB
Am J Physiol Heart Circ Physiol; 2020 Nov; 319(5):H1059-H1068. PubMed ID: 33036546
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management.
Wu L; O'Kane AM; Peng H; Bi Y; Motriuk-Smith D; Ren J
Biochem Pharmacol; 2020 Aug; 178():114114. PubMed ID: 32579957
[TBL] [Abstract][Full Text] [Related]
12. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
Malek Mahdavi A
Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
[TBL] [Abstract][Full Text] [Related]
13. Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease.
Ferrario CM; Ahmad S; Groban L
Clin Sci (Lond); 2020 Oct; 134(19):2645-2664. PubMed ID: 33063823
[TBL] [Abstract][Full Text] [Related]
14. Is amiloride a promising cardiovascular medication to persist in the COVID-19 crisis?
Adil MS; Narayanan SP; Somanath PR
Drug Discov Ther; 2020 Nov; 14(5):256-258. PubMed ID: 33116037
[TBL] [Abstract][Full Text] [Related]
15. Severe respiratory SARS-CoV2 infection: Does ACE2 receptor matter?
Perrotta F; Matera MG; Cazzola M; Bianco A
Respir Med; 2020 Jul; 168():105996. PubMed ID: 32364961
[TBL] [Abstract][Full Text] [Related]
16. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications.
Abassi Z; Assady S; Khoury EE; Heyman SN
Am J Physiol Heart Circ Physiol; 2020 May; 318(5):H1080-H1083. PubMed ID: 32223552
[No Abstract] [Full Text] [Related]
17. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
Brojakowska A; Narula J; Shimony R; Bander J
J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
[TBL] [Abstract][Full Text] [Related]
18. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
Sommerstein R; Kochen MM; Messerli FH; Gräni C
J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
[No Abstract] [Full Text] [Related]
19. Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin-Converting Enzyme 2.
Buckley LF; Cheng JWM; Desai A
J Cardiovasc Pharmacol; 2020 Jun; 75(6):526-529. PubMed ID: 32301766
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications.
Groß S; Jahn C; Cushman S; Bär C; Thum T
J Mol Cell Cardiol; 2020 Jul; 144():47-53. PubMed ID: 32360703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
